IVON-PP Trial: Intravenous Ferric Carboxymaltose Outperforms Oral Iron for Postpartum Anaemia in Nigeria
A recent open-label, randomised controlled trial published in The Lancet Global Health, titled IVON-PP, investigates the efficacy of intravenous ferric carboxymaltose compared to oral ferrous sulphate for treating moderate-to-severe postpartum anaemia in Nigerian women. The study results indicate that ferric carboxymaltose is significantly more effective than the traditional oral treatment option. Furthermore, the intravenous formulation was found to be well tolerated by the participants, suggesting a favorable safety profile alongside its superior therapeutic benefits. This research highlights a potential shift in clinical practice for managing postpartum anaemia in resource-limited settings, offering a more efficient alternative to standard oral iron supplements. The findings are particularly relevant for maternal health initiatives in Nigeria and similar regions where postpartum anaemia remains a critical public health challenge. By demonstrating the advantages of intravenous administration, the study provides evidence-based support for improving recovery outcomes for new mothers suffering from significant blood loss and iron deficiency following childbirth.
Wire timeline
IVON-PP Trial: Intravenous Ferric Carboxymaltose Outperforms Oral Iron for Postpartum Anaemia in Nigeria
A recent open-label, randomised controlled trial published in The Lancet Global Health, titled IVON-PP, investigates the efficacy of intravenous ferric carboxymaltose compared to oral ferrous sulphate for treating moderate-to-severe postpartum anaemia in Nigerian women. The study results indicate that ferric carboxymaltose is significantly more effective than the traditional oral treatment option. Furthermore, the intravenous formulation was found to be well tolerated by the participants, suggesting a favorable safety profile alongside its superior therapeutic benefits. This research highlights a potential shift in clinical practice for managing postpartum anaemia in resource-limited settings, offering a more efficient alternative to standard oral iron supplements. The findings are particularly relevant for maternal health initiatives in Nigeria and similar regions where postpartum anaemia remains a critical public health challenge. By demonstrating the advantages of intravenous administration, the study provides evidence-based support for improving recovery outcomes for new mothers suffering from significant blood loss and iron deficiency following childbirth.
The Lancet Global Health